O1385
Ozagrel hydrochloride hydrate
≥98% (HPLC), solid
Synonym(s):
(E)-3-[4-(Imidazol-1-ylmethyl)phenyl]propenoic acid hydrochloride hydrate, OKY-046
Sign In to View Organizational & Contract Pricing.
Select a Size
About This Item
Empirical Formula (Hill Notation):
C13H12N2O2 · HCl · xH2O
CAS Number:
Molecular Weight:
264.71 (anhydrous basis)
NACRES:
NA.77
PubChem Substance ID:
UNSPSC Code:
12352200
MDL number:
InChI
1S/C13H12N2O2.ClH.H2O/c16-13(17)6-5-11-1-3-12(4-2-11)9-15-8-7-14-10-15;;/h1-8,10H,9H2,(H,16,17);1H;1H2/b6-5+;;
SMILES string
O.Cl.OC(=O)\C=C\c1ccc(Cn2ccnc2)cc1
InChI key
OWIZTYOMGVTSDP-TXOOBNKBSA-N
assay
≥98% (HPLC)
form
solid
storage condition
desiccated
color
white to off-white
solubility
H2O: soluble
storage temp.
room temp
Quality Level
Related Categories
Application
Ozagrel hydrochloride hydrate has been used as a thromboxane synthase inhibitor:
- in high cholesterol-diet rats (HC) to test its effect on arteriolar constriction
- to pre-treat mice to test its effect on lipopolysaccharide (LPS)-induced behavioral changes
- to test its effect on arteriolar vasoconstriction in hyperglycemic mice
Biochem/physiol Actions
Ozagrel is a selective thromboxane A2 synthase (TXA2) inhibitor.
Ozagrel is useful in treating lacunar and thrombotic stroke. It blocks vasoconstriction and platelet aggregation. Ozagrel aids in improving the prostacyclin (PGI2)/ thromboxane A2 (TXA2) in the acute phase of cerebral ischemia. It improves endothelial dysfunction in L-methionine-induced hyperhomocysteinemia (HHcy)-induced vascular cognitive impairment and dementia (VCID).
Storage Class
11 - Combustible Solids
wgk
WGK 2
flash_point_f
Not applicable
flash_point_c
Not applicable
ppe
Eyeshields, Gloves, type N95 (US)
Choose from one of the most recent versions:
Already Own This Product?
Find documentation for the products that you have recently purchased in the Document Library.
Yukito Shinohara et al.
Cerebrovascular diseases (Basel, Switzerland), 27(5), 485-492 (2009-03-27)
Edaravone, a free radical scavenger approved by the Japanese Ministry of Health, Labor and Welfare in 2001 for treating acute ischemic stroke, was recommended by the Japanese Guidelines for the Management of Stroke 2004. While edaravone also has a neuroprotective
Yukiko Enomoto et al.
Atherosclerosis, 209(2), 415-421 (2009-11-26)
The plasma level of soluble CD40 ligand (sCD40L), which induces pro-inflammatory and pro-atherogenic responses, is known to be elevated in atherosclerotic patients. In this study, we investigated the mechanism of sCD40L release from human platelets, focusing on the involvement of
Sang In Park et al.
Brain research, 1599, 85-92 (2015-01-04)
We investigated the neuroprotective properties of single doses of minocycline and ozagrel when administered prior to stroke. Male Sprague-Dawley rats were assigned randomly to one of the following groups: (1) control (Con) group (n=10), (2) minocycline (Mino) group (n=10), (3)
Seungjun Lee et al.
Microvascular research, 76(3), 217-223 (2008-08-23)
Retinal blood flow decreases early in the progression of diabetic retinopathy; however, the mediators and mechanisms responsible for this decrease have yet to be determined. In this study, diabetes was induced by streptozotocin in rats, and retinal blood flow was
Pankaj Bhatia et al.
Fundamental & clinical pharmacology, 35(4), 650-666 (2020-10-07)
The present study investigates the effect of ozagrel, a selective thromboxane A2 (TXA2) inhibitor, in rat model of hyperhomocysteinemia (HHcy)-induced vascular cognitive impairment and dementia (VCID). Wistar rats were administered L-methionine (1.7 g/kg/day; p.o. × 8 weeks) to induce VCID. Morris water
Related Content
Instructions
Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.
Contact Technical Service